Interstitial Lung Disease and Anti-Myeloperoxidase Antibodies: Not a Simple Association.
anti-myeloperoxidase antibodies
idiopathic pulmonary fibrosis
interstitial pneumonia
rheumatic diseases
vasculitis
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
09 Jun 2021
09 Jun 2021
Historique:
received:
10
05
2021
revised:
31
05
2021
accepted:
07
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Anti-neutrophil cytoplasmic antibodies (ANCA), mainly anti-myeloperoxidase (MPO) antibodies, have been frequently identified in patients with idiopathic pulmonary fibrosis (IPF). However, their role remains unclear, and only 7-23% of these patients develops clinically overt vasculitis. We aimed to investigate the clinical, serological, and radiological features and prognosis of anti-MPO-positive interstitial lung disease (ILD) patients. Fifty-eight consecutive patients firstly referred for idiopathic interstitial pneumonia and showing serological positivity of anti-MPO antibodies were retrospectively enrolled. For each patient, clinical data, lung function testing, chest high-resolution computed tomography (HRCT) pattern, and survival were recorded. Thirteen patients developed a rheumatic disease during a median follow-up of 39 months. Usual interstitial pneumonia (UIP) was the most frequent ILD pattern, significantly influencing the patients' survival. In fact, while the 52-week survival of the overall population was 71.4 ± 7.5%, significantly higher than IPF, survivals of anti-MPO patients with UIP pattern and IPF were similar. Forced vital capacity and diffusion lung capacity for CO significantly declined in 37.7 and 41.5% of cases, respectively, while disease progression at chest HRCT was observed in 45.2%. A careful clinical history and evaluation should always be performed in ILD patients with anti-MPO antibodies to quickly identify patients who are developing a systemic rheumatic disease.
Identifiants
pubmed: 34207641
pii: jcm10122548
doi: 10.3390/jcm10122548
pmc: PMC8227546
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Rheumatol. 2015 Jul;34(7):1273-7
pubmed: 24863847
PLoS One. 2018 Jun 21;13(6):e0199659
pubmed: 29928060
J Autoimmun. 2020 Jan;106:102338
pubmed: 31570253
Radiology. 2004 Jul;232(1):81-91
pubmed: 15166329
Autoimmun Rev. 2015 Aug;14(8):742-50
pubmed: 25916811
Clin Rheumatol. 2015 Sep;34(9):1653-4
pubmed: 25980836
Autoimmun Rev. 2017 Jul;16(7):722-729
pubmed: 28479484
Autoimmun Rev. 2020 Feb;19(2):102451
pubmed: 31838159
Ann Intern Med. 1997 Jun 1;126(11):866-73
pubmed: 9163287
Scand J Rheumatol. 1999;28(4):254-6
pubmed: 10503564
N Engl J Med. 1988 Jun 23;318(25):1651-7
pubmed: 2453802
Joint Bone Spine. 2004 May;71(3):198-202
pubmed: 15182790
BMJ Open Respir Res. 2015 Jan 09;2(1):e000058
pubmed: 25593704
J Clin Rheumatol. 2020 Mar 31;:
pubmed: 32251058
Chest. 2019 Oct;156(4):715-723
pubmed: 31181198
Respiration. 2009;77(4):407-15
pubmed: 19077381
Respirology. 2016 Jul;21(5):920-6
pubmed: 26994375
Thorax. 2014 Mar;69(3):216-22
pubmed: 24127020
Respir Med. 2013 Apr;107(4):608-15
pubmed: 23434037
J Korean Med Sci. 2013 May;28(5):731-7
pubmed: 23678265
Clin Med Insights Circ Respir Pulm Med. 2015 Sep 23;9(Suppl 1):51-6
pubmed: 26448696
Eur Respir J. 2015 Oct;46(4):976-87
pubmed: 26160873
BMC Pulm Med. 2021 Mar 16;21(1):88
pubmed: 33726733
Semin Respir Crit Care Med. 2018 Aug;39(4):465-470
pubmed: 30404113
Arthritis Rheum. 2013 Jan;65(1):1-11
pubmed: 23045170
Lancet Respir Med. 2018 Feb;6(2):138-153
pubmed: 29154106
Clin Exp Rheumatol. 2020 Mar-Apr;38 Suppl 124(2):221-231
pubmed: 32324122
Am J Respir Crit Care Med. 2008 Jun 15;177(12):1338-47
pubmed: 18388353
Ryumachi. 1995 Feb;35(1):46-55
pubmed: 7732490
Rheumatology (Oxford). 2011 Nov;50(11):2035-43
pubmed: 21873269